Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep

The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study

“…This supports use of the ARIA score to assess AR control using mobile technology. The WPAI‐AS scores observed in the study are lower than those reported in patients selected by physicians . This is because many users have mild rhinitis whereas in clinical trials or in patients selected by physicians, AR is usually more severe.…”

Effect of topical corticosteroids on allergic airway inflammation and disease severity in obstructive sleep apnoea

“…In addition, the allergic group showed a statistically significant improvement in the supine AHI score compared with non-allergic subjects after a course of intranasal corticosteroids. A recent study investigating the impact of inhaled mometasone therapy in patients with allergic rhinitis did not show the same improvement in AHI observed in this study; however, improvements in other sleep parameters, including nasal symptoms and subjective sleep assessments were seen [32]. One possible explanation of the variable impact of nasal steroid treatment on AHI may be related to the duration of treatment.…”

Objective reduction in adenoid tissue after mometasone furoate treatment

“…Topical nasal corticosteroids have proved to be the most effective treatment to control symptoms related to allergic rhinitis, particularly nasal obstruction [2][3][4][5][6]. Among the available corticosteroids for clinical use, mometasone furoate safety is well established in children older than 2 years [7][8][9][10].…”